Paying users zone. Data is covered by 
.
Get 1 month access to Bristol-Myers Squibb Co. for $17.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
Bristol-Myers Squibb Co. (BMY)
Statement of Financial Position, Liabilities and Stockholders’ Equity
Quarterly Data
Difficulty: Beginner
The statement of financial position provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.
Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.
Bristol-Myers Squibb Co., Consolidated Statement of Financial Position, Liabilities and Stockholders’ Equity (quarterly data)
USD $ in millions
Based on: 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28), 10-K (filing date: 2015-02-13), 10-Q (filing date: 2014-10-24), 10-Q (filing date: 2014-07-24), 10-Q (filing date: 2014-04-29).
| Item | Description | The company |
|---|---|---|
| Current liabilities | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. | Bristol-Myers Squibb Co.’s current liabilities increased from Q3 2018 to Q4 2018 but then declined significantly from Q4 2018 to Q1 2019. |
| Noncurrent liabilities | Amount of obligation due after one year or beyond the normal operating cycle, if longer. | Bristol-Myers Squibb Co.’s noncurrent liabilities declined from Q3 2018 to Q4 2018 but then increased from Q4 2018 to Q1 2019 exceeding Q3 2018 level. |
| Total liabilities | Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. | Bristol-Myers Squibb Co.’s total liabilities increased from Q3 2018 to Q4 2018 but then declined significantly from Q4 2018 to Q1 2019. |
| Total Bristol-Myers Squibb Company shareholders’ equity | Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. | Bristol-Myers Squibb Co.’s total Bristol-Myers Squibb Company shareholders’ equity increased from Q3 2018 to Q4 2018 and from Q4 2018 to Q1 2019. |